Sean Maduck - Sep 3, 2024 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Stock symbol
CORT
Transactions as of
Sep 3, 2024
Transactions value $
$7,501
Form type
4
Date filed
9/5/2024, 08:08 PM
Previous filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Tax liability -$8.19K -232 -0.27% $35.30 84.2K Sep 3, 2024 Direct F1, F2, F3
transaction CORT Common Stock Award $15.7K +458 +0.54% $34.26 84.6K Sep 3, 2024 Direct F3, F4, F5
transaction CORT Common Stock Award $0 +458 +0.54% $0.00 85.1K Sep 3, 2024 Direct F3, F6
holding CORT Common Stock 10K Sep 3, 2024 See Footnote F7
holding CORT Common Stock 10K Sep 3, 2024 See Footnote F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F2 The closing price on August 30, 2024 was used to calculate the withholding obligation.
F3 Includes 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 3, 2024.
F5 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F6 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F7 Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F8 Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.